Leap Therapeutics, Inc.

NasdaqCM LPTX

Leap Therapeutics, Inc. Price to Book Ratio (P/B) on January 14, 2025

Leap Therapeutics, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Leap Therapeutics, Inc. 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Leap Therapeutics, Inc. 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Leap Therapeutics, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: LPTX

Leap Therapeutics, Inc.

CEO	Mr. Douglas E. Onsi J.D.
IPO Date	Jan. 25, 2017
Location	United States
Headquarters	47 Thorndike Street
Employees	54
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years